Canadian Hospital Specialties Limited acquires all product lines from Roxon Medi-Tech Ltd.

1 minute read
16 February 2021

On February 16, 2021, Canadian Hospital Specialties Limited ("CHS") announced the acquisition of all product lines (excluding urology products) from Roxon Medi-Tech Ltd.  

CHS, a portfolio company of private equity firm Cortec Group, is a national specialty distributor of medical and surgical products focused on strategic partnerships to enhance the experience of its customers while focusing on improving patient outcomes.

The acquisition of Roxon will broaden CHS's footprint in the Cardiac Diagnostics and Monitoring and Neuro Monitoring spaces.  It also adds a Pulmonary testing portfolio to the existing Respiratory platform and augments the existing Pharmacy portfolio for both the acute and non-acute channel with the refrigeration portfolio.

Gowling WLG advised CHS in this acquisition with a team that included Ian Palm, David Torchetti and Aaron Goldstein.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.